Journal article

Between a shock and a hard place: challenges and developments in HIV latency reversal

Jennifer M Zerbato, Harrison V Purves, Sharon R Lewin, Thomas A Rasmussen

Current Opinion in Virology | ELSEVIER SCI LTD | Published : 2019


Latently infected cells that persist in HIV-infected individuals on antiretroviral therapy (ART) are a major barrier to cure. One strategy to eliminate latency is by activating viral transcription, commonly called latency reversal. Several small non-randomised clinical trials of latency reversing agents (LRAs) in HIV-infected individuals on ART increased viral production, but disappointingly did not reduce the number of latently infected cells or delay time to viral rebound following cessation of ART. More recent approaches aimed at reversing latency include compounds that both activate virus and also modulate immunity to enhance clearance of infected cells. These immunomodulatory LRAs inclu..

View full abstract


Awarded by National Institutes of Health

Awarded by American Foundation for AIDS Research

Funding Acknowledgements

This work was partly supported by funding from the National Health and Medical Research Council (NHMRC) of Australia and the National Institutes of Health, (UM lAI126611, Delaney AIDS Research Enterprise (DARE) to find a cure) and the American Foundation for AIDS Research (amfAR 109226-58-RGRL). S.R.L. is an NHMRC Practitioner Fellow.